Related Experiment Video
Updated: Jan 22, 2026

Oral Biofilm Sampling for Microbiome Analysis in Healthy Children
Published on: December 31, 2017
Lamivudine therapy for chronic hepatitis B in children: a meta-analysis
Aoran Luo1, Xiaoyan Jiang1, Hong Ren2
1Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, 1 Yixueyuan Road, Chongqing, 400010, People's Republic of China.
Background:
Currently, there is no consensus on the effects and safety of lamivudine therapy for chronic hepatitis B (CHB) in children.
Method:
Both English and Chinese databases were searched comprehensively. An odds ratio (OR) and a standard mean difference (SMD) were used to assess the effects and safety of lamivudine therapy for CHB in children.
Results:
Thirteen eligible studies were included in our analysis. The rates of Hepatitis B virus (HBV) response, biochemical response, hepatitis B e antigen (HBeAg) loss, HBeAg seroconversion, and hepatitis B surface antigen (HBsAg) loss were significantly higher in the lamivudine (LAM) therapy group than in the control group. The changes in children's weight and height were similar between the two groups.
Conclusions:
LAM therapy was efficacious for CHB in children. Additionally, it had no side effect on children's height and weight.
Related Concept Videos
Directing Effect of Substituents: meta-Directing Groups
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
Gene Therapy
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Group Therapy

